Achaogen promotes three executives
Blake Wise has been appointed President and Chief Operating Officer. He joined Achaogen in 2015 as Achaogen’s Chief Operating Officer.
Prior to joining Achaogen, Mr. Wise held increasingly responsible positions at Genentech, most recently as Vice President, Cross BioOncology.
Mr. Wise received a Bachelor of Arts degree in Business Economics from University of California, Santa Barbara, and a Masters of Business Administration degree from the University of California, Berkeley Haas School of Business.
Lee Swem has been promoted to Senior Vice President and Chief Scientific Officer.
Dr. Swem has joined Achaogen in 2013 as the Director of the Therapeutic Antibody Program, where he developed a state-of-the-art antibody discovery platform to rapidly identify rare functional antibodies to treat serious human infectious diseases.
In 2015, he was appointed Vice President, Head of Research.
Prior to Achaogen, Dr. Swem was a Scientist in the Department of Infectious Disease at Genentech where he developed programs in anti-influenza A and B, and began a small molecule anti-bacterial program.
Dr. Swem received his Ph.D. from Indiana University followed by postdoctorate research at Princeton University.
Zeryn Sarpangal has been promoted to Senior Vice President of Corporate and People Strategy.
Ms. Sarpangal has been at Achaogen for more than six years and has held various roles in the organization including Sr. Director of Finance & Operations and Director of Strategic Marketing.
In 2015, Ms. Sarpangal was promoted to Vice President of Human Resources and Corporate Affairs. From 2012 to 2013, she was Vice President of Finance & Operations at Identified, an HR data analytics company, that was acquired by Workday.
Prior to joining Achaogen, Ms. Sarpangal was an engagement manager at McKinsey & Company focused on social sector organizations and biopharmaceutical companies, and prior to that, a healthcare investment banking analyst at Goldman, Sachs & Co.
Ms. Sarpangal received a Bachelor of Arts in Economics and Molecular & Cell Biology from University of California, Berkeley, and a Masters of Business Administration from the Stanford Graduate School of Business. ■
What to read next
LATEST MOVES FROM California
- Impax Laboratories appoints Paul M. Bisaro as CEO
- Retrophin names John A. Orwin to board
- Intel appoints two to board
- Walt Disney Company extends CEO's contract to 2019
- Ekso Bionics adds Howard Palefsky to board
More inside POST
Employees leave the way you treat them Leadership